HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Telbivudine/Torcitabine Idenix/Novartis.

Abstract
Idenix (formerly Novirio) and Novartis are developing two beta-L-deoxynucleosides, telbivudine and torcitabine, for the potential treatment of hepatitis B virus infection. Phase III trials of telbivudine were underway by August 2002 and phase I/II trials of the torcitabine prodrug, valtorcitabine, were ongoing in November 2003.
AuthorsR Anthony Vere Hodge
JournalCurrent opinion in investigational drugs (London, England : 2000) (Curr Opin Investig Drugs) Vol. 5 Issue 2 Pg. 232-41 (Feb 2004) ISSN: 1472-4472 [Print] England
PMID15043399 (Publication Type: Journal Article, Review)
Chemical References
  • Antiviral Agents
  • Drugs, Investigational
  • Nucleosides
  • Pyrimidinones
  • Telbivudine
  • 1-(2-deoxy-beta-L-erythropentafuranosyl)-5-methyl-2,4(1H)-pyrimidinone
  • Thymidine
Topics
  • Animals
  • Antiviral Agents (chemistry, pharmacology, therapeutic use)
  • Clinical Trials as Topic (statistics & numerical data)
  • Drugs, Investigational (chemistry, pharmacology, therapeutic use)
  • Hepatitis B (drug therapy, metabolism)
  • Hepatitis B virus (drug effects, metabolism)
  • Humans
  • Nucleosides (chemistry, pharmacology, therapeutic use)
  • Pyrimidinones (chemistry, pharmacology, therapeutic use)
  • Technology, Pharmaceutical (methods)
  • Telbivudine
  • Thymidine (analogs & derivatives)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: